Caron-Lapointe G

Analysis Group, Inc, Montréal, QC, Canada.

2 papers

ArticleKetamine

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.

Teeple A, Zhdanava M, Pilon D +3

Europe PMC2023
ArticleKetamine

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Zhdanava M, Teeple A, Pilon D +3

Europe PMC2023